Endocrinology Today—December 9, 2025

Catch the latest endocrinology news, featuring industry updates, clinical progress, and biopharma innovations.

In Today’s Newsletter

Dive deeper

🦴 CGMs Measuring Alternative Biofluids Show Potential in Diabetes Care [1] [US • 4 Dec 2025]

https://www.pharmacytimes.com/view/cgms-that-measure-alternative-biofluids-show-potential-in-diabetes-care

Context: Research highlights the potential of these new biosensor technologies to provide real-time, continuous glucose tracking, reducing reliance on traditional blood-based methods.

Key point: CGM technology is advancing with the use of alternative biofluids like sweat, saliva, and interstitial fluid, offering a non-invasive approach to glucose monitoring.

Implication: This could significantly improve diabetes management, making it more accessible and comfortable for patients, especially with the growing integration of AI for predictive insights.

🧠 Medtronic Rolls Out MiniMed 780G with Abbott’s Instinct Sensor [2] [US • 2 Dec 2025]

https://www.drugdeliverybusiness.com/medtronic-full-launch-minimed-780g-abbott-instinct/

Context: This system allows for real-time glucose monitoring and automated insulin adjustments every five minutes, providing enhanced control over diabetes management.

Key point: Medtronic’s MiniMed 780G insulin pump, paired with Abbott’s Instinct sensor, is now commercially available in the U.S.

Implication: This new system will likely reduce the complexity of daily diabetes care, offering more freedom and greater control for users.

❤️ Cardiac Screening Tools Fail to Identify Many Patients at Risk [3] [Sweden • 3 Dec 2025]

https://www.rheumatologyadvisor.com/news/cardiac-screening-tools-fail-to-identify-many-patients-at-risk/

Context: A study of over 160,000 patients found that tools like the ASCVD Risk Estimator Plus failed to identify many at-risk individuals, particularly those with no prior coronary artery disease.

Key point: Current cardiac screening tools are missing many younger patients at risk for acute coronary syndrome (ACS).

Implication: This raises concerns about the accuracy of population-based screening tools, suggesting the need for more individualized assessments.

🤰 Untargeted Metabolomics Study Identifies Metabolic Profiles Linked to Polycystic Ovary Syndrome (PCOS) [4] [US • 2 Dec 2025]

https://www.geneonline.com/untargeted-metabolomics-study-identifies-metabolic-profiles-linked-to-polycystic-ovary-syndrome/

Context: Using mass spectrometry, this untargeted study uncovered a wide range of metabolites associated with PCOS, a common endocrine disorder.

Key point: Advanced metabolomics has identified distinct metabolic profiles in patients with PCOS, offering potential biomarkers for diagnosing and treating the condition.

Implication: These findings may lead to new biomarkers and therapeutic targets for PCOS, improving diagnosis and treatment for this common endocrine disorder.

🧪 New Targeted Alpha Therapy Shows Promise for Patients with Radioiodine-Refractory Thyroid Cancer [5] [US • 5 Dec 2025]

https://www.news-medical.net/news/20251205/New-targeted-alpha-therapy-shows-promise-for-patients-radioiodine-refractory-thyroid-cancer.aspx

Context: In a Phase I trial, the therapy demonstrated both tolerability and disease control, providing a promising new treatment for radioiodine-refractory thyroid cancer.

Key point: A novel alpha-emitting radionuclide therapy using 211At has shown promise in controlling disease in patients with thyroid cancer that is resistant to radioactive iodine.

Implication: This could offer a new therapeutic option for patients who have exhausted traditional treatment options, improving their prognosis and quality of life.

💉 Debiopharm Randomizes First Patient in Phase III Acromegaly Trial [6] [Global • 5 Dec 2025]

https://www.clinicaltrialsarena.com/news/debiopharm-first-patient-acromegaly-trial/?cf-view

Context: This global trial involves 120 patients and will assess whether Debio 4126 can provide sustained biochemical control of acromegaly with fewer injections.

Key point: Debiopharm has initiated a Phase III clinical trial to evaluate Debio 4126, a long-acting treatment for acromegaly that reduces the frequency of injections from 12 to 4 per year.

Implication: This treatment could significantly improve patient adherence and quality of life by reducing the burden of frequent injections.

⚠️ Abbott Diabetes Care Glucose Monitor Recall [7] [US • 3 Dec 2025]

https://www.cbsnews.com/news/abbott-diabetes-care-glucose-monitor-freestyle-libre-3-plus-sensor-recall/

Context: The faulty sensors have been linked to hundreds of adverse events, including deaths, as patients mismanage insulin dosages based on inaccurate glucose data.

Key point: Abbott is recalling certain FreeStyle Libre 3 and Libre 3 Plus sensors due to incorrect low glucose readings, which could lead to dangerous health consequences.

Implication: Patients are advised to stop using affected devices and request replacements to avoid health risks associated with inaccurate readings.

💉 Eli Lilly’s Mounjaro Added to China’s State Insurance List for Diabetes Treatment [8] [China • 8 Dec 2025]

https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lillys-mounjaro-added-chinas-state-insurance-list-diabetes-treatment-2025-12-08/

Context: This inclusion will make the drug more accessible and affordable for the 1.4 billion people in China, a country with a significant diabetes burden.

Key point: Mounjaro, Eli Lilly’s diabetes medication, will be included in China’s national health insurance scheme starting January 1, 2026.

Implication: With the added insurance coverage, Mounjaro will likely see increased adoption in China, improving treatment outcomes for diabetes patients.

🧪 Biorep Technologies Announces First Successful Independent Research Use of the PRISM System in Islet Isolation [9] [US • 8 Dec 2025]

https://www.biospace.com/press-releases/biorep-technologies-announces-first-successful-independent-research-use-of-the-prism-system-in-islet-isolation

Context: The PRISM system provides reproducible and reliable islet isolations, offering a modern, automated solution for research labs.

Key point: Biorep’s PRISM system has been successfully used for independent islet isolation, marking a significant step in advancing pancreatic research.

Implication: This system could become the gold standard for islet research, supporting studies into diabetes treatments and improving islet transplantation methods.

Why it matters

Diabetes & Technology: New glucose monitoring methods, such as those using alternative biofluids, are enhancing accessibility and accuracy for patients with diabetes.
Cancer Treatments: Innovative therapies, like targeted alpha therapy for thyroid cancer, offer patients with limited treatment options a new chance for disease control.
PCOS: The identification of metabolic profiles in PCOS patients could lead to better diagnostics and treatments for the condition.
Medical Devices: The recall of faulty glucose monitors highlights the importance of ensuring accurate and safe devices for chronic disease management.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Endocrinology archive on our research hub page.

FAQ

What is the FreeStyle Libre 3 recall about?

The recall involves malfunctioning sensors in certain FreeStyle Libre 3 and Libre 3 Plus devices that may give incorrect low glucose readings, leading to mismanagement of diabetes [7].

When will Mounjaro be available in China?

Mounjaro, Eli Lilly’s diabetes medication, will be added to China’s insurance list starting January 1, 2026, making it more accessible to patients with type 2 diabetes [8].

How will the PRISM system affect research?

The PRISM system has been successfully used for islet isolation, potentially improving research reliability and advancing diabetes and transplantation studies [9].

Entities / Keywords

Continuous Glucose Monitoring (CGM); Abbott Diabetes Care; Medtronic MiniMed 780G; Acromegaly; Thyroid Cancer; Mounjaro; PRISM System; Islet Isolation; FreeStyle Libre 3; Diabetes Care Technology; Targeted Alpha Therapy; Polycystic Ovary Syndrome (PCOS)